Short answer
Viatris (VTRS) filed its Q1 2025 10-Q quarterly report on May 8, 2025 for the quarter ended Mar 31, 2025. Quarterly revenue was $3.2B (down 11.2% year over year) with net income of −$3.0B.
Q1 2025 key financials · XBRL
- Revenue
- $3.2B
- −11.2% YoY
- Net income
- −$3.0B
- −2770.8% YoY
- Operating margin
- -88.9%
- Gross margin
- 35.8%
- EPS (diluted)
- −$2.55
- −2933.3% YoY
Source: XBRL data from the Viatris (VTRS) Q1 2025 10-Q on SEC EDGAR. USD.
Viatris Q1 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: Potential U.S. tariffs on pharmaceutical imports triggered by recent tariff escalations and retaliations from other countries
- Most material update: Increased cost and supply chain disruption risk from proposed tariffs affecting generics, possibly reducing net sales and profit margins
- Regulatory risk: Need for regulatory approval before changing manufacturing locations or suppliers limits flexibility amid trade restrictions
- Operational risk: Supply chain disruptions and manufacturing delays due to tariffs or domestic sourcing requirements threaten near-term production continuity
- Financial risk: Tariff-related cost increases may reduce cash flows and impair ability to pay dividends or repurchase shares
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Viatris quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.